Format

Send to

Choose Destination
PLoS One. 2009;4(5):e5263. doi: 10.1371/journal.pone.0005263. Epub 2009 May 6.

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.

Author information

1
Division of Gastroenterology and Hepatology, Department of Clinical Sciences Malmö, Lund University, University Hospital MAS, Malmö, Sweden. olof.grip@med.lu.se

Abstract

BACKGROUND:

In Crohn's disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease.

METHODOLOGY/PRINCIPAL FINDINGS:

We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn's disease patients before and after thirteen weeks' daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in all of the treated patients. Levels of CXCL10 correlated with C-reactive protein (r = 0.82, p<0.01).

CONCLUSIONS/SIGNIFICANCE:

CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin may represent a candidate for an approach to the treatment of Crohns disease in the future.

TRIAL REGISTRATION:

(ClinicalTrials.gov) NCT00454545.

PMID:
19421322
PMCID:
PMC2674206
DOI:
10.1371/journal.pone.0005263
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center